Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06353529 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Postop Pain Management in Pituitary Tumour Patients

Study acronym: POPPY
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 12, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Nov 2025 to Apr 2026
    • Study completion date: Jan 2026 to Jul 2026
    • Publications: details revised at 5 of 5 entries
    v3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 9 more changesShow less
    • Enrollment target: 52 to 108
    • Start date changed from estimate of May 2024 to Nov 25, 2024
    • Primary completion date: May 2025 to Nov 2025
    • Study completion date: May 2025 to Jan 2026
    • Interventions: Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution (Drug), Placebo (Drug) to Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution (Drug), Placebo (Drug), Sham Comparator (Drug)
    • Site details revised
    • Publications: details revised at 5 of 5 entries
    • Study title revised
    • Study arms: 2 to 3
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To assess the benefit of using an additional nerve block during minimally invasive pituitary surgery, to improve pain management after surgery. The medication (Bupivacaine) or a placebo (saline) will be injected during surgery and patients will be asked about their level of pain at multiple time points in the first 24 hours following surgery. Some patients will be randomized to a third, sham group that do not receive any additional injection. The aim is to improve patient outcomes and reduce the need for pain medication after surgery.
Trial Details
NCT Number NCT06353529
Lead Sponsor Hamilton Health Sciences Corporation
Conditions
(from sponsor)		 Pituitary, Pain, Postoperative
Related terms Pituitary Diseases, Postoperative Pain
Enrollment 108 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov